A new resorbable magnesium scaffold (DREAMS 3G): 12-month vasomotion results from the BIOMAG-I first-in-human study

被引：0
|
作者：
Haude, Michael [1 ]
Iglesias, Juan F. [2 ]
Garcia-Garcia, Hector M. [3 ]
Barlagiannis, Dimitrios [1 ]
Degrauwe, Sophie [2 ]
Melaku, Gebremedhin [3 ]
Beyene, Solomon [3 ]
Waksman, Ron [3 ]
机构：
[1] Rheinland Klinikum Neuss GmbH Lukaskrankenhaus, Med Clin I, Neuss, Germany
[2] Geneva Univ Hosp, Dept Cardiol, Geneva, Switzerland
[3] MedStar Washington Hosp Ctr, Intervent Cardiol, Washington, DC USA
来源：
EUROINTERVENTION | 2024年 / 20卷 / 17期
关键词：
D O I：
10.4244/EIJ-D-24-00355
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：e1118 / e1120
页数：3
相关论文
共 28 条
  • [21] Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma.
    Sun, Mingyuan
    Qiu, Lugui
    Wei, Yongqiang
    Jin, Jie
    Li, Xin
    Liu, Xue
    Yin, Shaohong
    Qi, Junyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study
    Zhao, H.
    Ma, Y.
    Meng, X.
    Wu, L.
    Fan, Y.
    Zheng, Y.
    Liu, Z.
    Ji, Y.
    Lv, D.
    Luo, S.
    Sommerhalder, D.
    Fu, S.
    Huang, Y.
    Yang, Y.
    Fang, W.
    Zhao, Y.
    Wang, Y.
    Chin, S.
    Xue, T.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S485 - S485
  • [23] BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: Updated results from first-in-human phase I study
    Zhang, L.
    Ma, Y.
    Zhao, Y.
    Fang, W. F.
    Zhao, H.
    Huang, Y.
    Yang, Y.
    Hou, X.
    Wen, Z.
    Zhang, S.
    Wang, J.
    Xiao, S.
    Wang, H.
    Zhu, H.
    Olivo, M. S.
    Zhu, Y.
    ANNALS OF ONCOLOGY, 2023, 34
  • [24] Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors.
    Powderly, John D.
    Jang, Sekwon
    Lohr, Joanna
    Spira, Alexander, I
    Bohac, Gerry C.
    Sharma, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Preliminary phase I results from a first-in-human study of ZG006, a trispecific anti-T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer or neuroendocrine carcinoma
    Wang, Q.
    Chai, X.
    Lin, R.
    Zheng, L.
    Cao, D.
    Qu, X.
    Liu, L.
    Wu, L.
    Mou, H.
    Xu, Q.
    Shi, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S532 - S533
  • [26] A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1.
    Iyer, Gopa
    Ebi, Hiromichi
    Cook, Natalie
    Gao, Xin
    Kitano, Shigehisa
    Matsubara, Nobuaki
    Reimers, Melissa A.
    Siefker-Radtke, Arlene O.
    Kim, Miso
    Galsky, Matthew D.
    Robbrecht, Debbie G. J.
    Guo, Jun
    Eigl, Bernhard J.
    Schaverien, Clare
    Butts, Brent
    Yuen, Eunice
    Szymczak, Sylwia
    Zhao, Xiang
    Widau, Ryan C.
    Drakaki, Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [27] Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
    Krishnan, Amrita Y.
    Minnema, Monique C.
    Berdeja, Jesus G.
    Oriol, Albert
    van de Donk, Niels W. C. J.
    Rodriguez-Otero, Paula
    Askari, Elham
    Mateos, Maria-Victoria
    Costa, Luciano J.
    Verona, Raluca I.
    Ma, Xuewen
    Girgis, Suzette
    Yang, Shiyi
    Hilder, Brandi W.
    Russell, Jeffery
    Goldberg, Jenna D.
    Chari, Ajai
    BLOOD, 2021, 138
  • [28] EuroIntervention in the top quartile of cardiovascular journals; QFR as a predictor for MI; mechanisms of ostial right coronary artery in-stent restenosis; thrombectomy and no-reflow in the TOTAL Trial; 10-year results of biodegradable polymer drug- eluting stents; the new-generation DREAMS 3G magnesium scaffold; outcomes of the BASILICA technique; paravalvular leak closure with vascular plugs; right heart remodelling with the TricValve; and more
    Capodanno, Davide
    EUROINTERVENTION, 2023, 19 (05) : 1 - 3
123